Healwell AI Advances Commercial Strategy with New Clinical Trial Platform

Healwell AI and WELL Health launch WELLTRUST™, an AI platform to streamline clinical trial patient recruitment with a privacy-first, consent-based approach across Canadian clinics.

Healwell AI has taken a significant step in commercializing its technology through a partnership with WELL Health. The collaboration has launched an artificial intelligence platform designed to streamline the search for clinical trial participants, targeting a major bottleneck in medical research while emphasizing data privacy and patient consent.

Strategic Partnership Drives Commercial Application

The newly introduced system, named WELLTRUST™, is being deployed across WELL Health's Canadian clinic network. It aims to solve the persistent challenge of patient recruitment for clinical studies. At its core is Healwell's proprietary DARWEN™ AI engine, which identifies suitable patients—particularly those managing chronic or complex conditions—who have explicitly provided consent to be contacted.

This "consent-first" methodology offers research institutions a privacy-compliant pathway to locate potential candidates, which could substantially improve clinical trial success rates. Patients retain greater control, with the ability to revoke permissions at any time. By integrating Healwell's AI capabilities with WELL Health's extensive clinical footprint, the initiative seeks to achieve scalable patient identification.

Integration Efforts Begin to Yield Results

The platform launch represents more than a new product for Healwell; it is a direct outcome of recent consolidation within its technology portfolio. The company has successfully merged its Khure and Pentavere technologies into a unified engine powered by DARWEN™. This consolidation creates opportunities for up-selling and cross-selling to the existing client base. Furthermore, the expansion of AI features, such as "Smart Search" within the Orion Health platform, underscores a strategic focus on embedding AI tools deeply into established medical software ecosystems.

Despite these operational developments, Healwell's shares continue to face market pressure. Trading at approximately 0.40 euros, the stock has declined by roughly 24 percent since the start of the year, reflecting ongoing sector-wide investor caution.

Commercialization Takes Center Stage

The introduction of WELLTRUST™ signals a shift for Healwell from pure technology development to tangible commercial deployment within a major network. The strategy's success will now hinge on the adoption rate among research organizations and whether the efficiency gains in patient recruitment translate into measurable revenue for the company in a timely manner.